Andrews 3/27/00 SP1 Pregnancy Follow-up Studies Lessons from Glaxo Wellcome Experience.

Slides:



Advertisements
Similar presentations
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Advertisements

Case Identification for the Missouri Perinatal Hepatitis B Prevention Program Libby Landrum, RN, MSN Viral Hepatitis Prevention Manager Bureau HIV, STD,
Study Designs in Epidemiologic
STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.
1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.
Mitochondrial Manipulation Technologies: Preclinical Considerations
Drug Utilization Review (DUR)
Elements of a clinical trial research protocol
Michigan Birth Defects Registry Overview and Status.
Environmental Health III. Epidemiology Shu-Chi Chang, Ph.D., P.E., P.A. Assistant Professor 1 and Division Chief 2 1 Department of Environmental Engineering.
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
Benefits for using a standardised risk management framework to risk assess Infection Prevention and Control Sue Greig Senior Project Officer National.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
COHORT STUDY DR. A.A.TRIVEDI (M.D., D.I.H.) ASSISTANT PROFESSOR
1 Alvimopan RiskMAP Joyce Weaver, Pharm.D., BCPS Office of Surveillance and Epidemiology.
DSaRM Advisory Committee May 18, 2005 Active Surveillance for Drug Safety Signals: Past, Present, and Future Mary Willy, Ph.D. Division of Drug Risk Evaluation.
1 Core Concepts: CDC Ethics Hypothesis Human subjects Prevalence rate Person, place, and time Surveillance Survey questions Lessons: 1-1 Introduction to.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Lecture 8 Objective 20. Describe the elements of design of observational studies: case reports/series.
ATP NVAC PIWG Report Pandemic Influenza Antiviral Strategies and Priority Groups Andrew T. Pavia M.D. University of Utah.
Study Design. Study Designs Descriptive Studies Record events, observations or activities,documentaries No comparison group or intervention Describe.
1 TYSABRI Risk Management Plan Will Maier, PhD Senior Director, Epidemiology.
Pregnancy Registries’ Contribution to Informed Clinical Practice Third Annual International Conference for Individualized Pharmacotherapy in Pregnancy.
Retrospective Cohort Study. Review- Retrospective Cohort Study Retrospective cohort study: Investigator has access to exposure data on a group of people.
Study Designs Afshin Ostovar Bushehr University of Medical Sciences Bushehr, /4/20151.
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
XXX_DECRIPT_MON00/1 Quality and impact of Social Science and Operations Research by the Special Programme in Human Reproduction Department of Reproductive.
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
RTI Health Solutions Practical and Methodological Issues in Long-Term Follow-Up Studies Elizabeth B. Andrews, Ph.D. Vice President, RTI Health Solutions.
OTIS ANNUAL RESEARCH MEETING JUNE 2010 Vaccines and Medications in Pregnancy Surveillance System (VAMPSS)
DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.
Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, 2004 RISK MANAGEMENT OPTIONS FOR PREGNANCY.
Cohort Study. Objectives To discuss cohort study designs To discuss data from some cohort studies.
Sidney M. Wolfe M.D and Sherri Shubin M.D., M.P.H. Public Citizen’s Health Research Group FDA Drug Safety and Risk Management and Dermatologic and Ophthalmic.
Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.
LEADING RESEARCH… MEASURES THAT COUNT Challenges of Studying Cardiovascular Outcomes in ADHD Elizabeth B. Andrews, MPH, PhD, VP, Pharmacoepidemiology and.
Use of Registries in Product Safety Assessment Kathryn Starzyk Outcome Sciences.
DODAC and DSaRM Advisory Committee August 1, 2007 Pregnancy Registry and Root Cause Analysis Cynthia Kornegay, Ph.D. Division of Drug Risk Evaluation Office.
History of Pediatric Labeling
HIV DISEASE IN PREGNANCY
(Slide 1 of 22) Response to the National Vaccine Advisory Committee Recommendations on the Immunization Safety Office Scientific Agenda Frank DeStefano,
FDA Risk Management Workshop – Day #3 April 11, 2003 Robert C. Nelson, Ph.D. RCN Associates, Inc Annapolis, MD, USA.
Predicting Pregnancy Risk among Women Attending an STD Clinic Judith Shlay MD, MSPH Denver Public Health September 21, 2008 CityMatCH Conference.
TERATOLOGY INFORMATION SERVICES
Accutane FDA (Section Name - Saver’s Initials) 3/9/00 12:50 PM 1 Risk Management Options Russell Ellison, MD Chief Medical Officer Vice President, Medical.
Descriptive study design
CCEB October 30 David J. Margolis MD PhD Associate Professor of Dermatology and Epidemiology Center for Clinical Epidemiology and Biostatistics University.
Biotechnology Industry Organization (BIO) Risk Management Public Workshop Day 1 - April 9, 2003 Risk Assessment in Drug and Biological Development Joanna.
Analytical Studies Case – Control Studies By Dr. Sameh Zaytoun (MBBch, DPH, DM, FRCP(Manch), DTM&H(UK),Dr.PH) University of Alexandria - Egypt Consultant.
Types of Studies. Aim of epidemiological studies To determine distribution of disease To examine determinants of a disease To judge whether a given exposure.
Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.
Drug Safety and Risk Management Advisory Committee May 18 & 19, 2005 PREGNANCY EXPOSURE REGISTRIES: MONITORING RISK FROM DRUG EXPOSURE IN PREGNANCY Kathleen.
Comments on FDA Concept Paper Sidney N. Kahn, MD, PhD President Pharmacovigilance & Risk Management, Inc. Risk Assessment of Observational.
BACKGROUND Despite the well established link between fetal macrosomia and maternal diabetes, it is estimated that 80% of macrosomic babies are born to.
Accutane ® Use and Epidemiology John E. La Flore, MD, MSPH Vice President, Drug Safety & Risk Management Hoffmann-La Roche Inc.
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
Drug Utilization Review & Drug Utilization Evaluation: An Overview
A proposed process for participatory decision on standards of care Daniel Tarantola, M.D., The University of New South Wales, Sydney, Australia IAS Conference,
Use of Acyclovir, Valacyclovir, and Famciclovir in the First Trimester of Pregnancy and the Risk of Birth Defects Björn Pasternak; Anders Hviid R3 Jungwook.
Journal Club Curriculum-Study designs. Objectives  Distinguish between the main types of research designs  Randomized control trials  Cohort studies.
Is a Clinical Trial Right for Me?
Regulatory Considerations for Approval: FDA perspective
Detection & monitoring of ADR
Module 4 (e) Pregnancy and Breast Feeding
Strategies to Reduce Antibiotic Resistance and to Improve Infection Control Robin Oliver, M.D., CPE.
Study design V: Case-Control Studies
Adele Schwartz Benzaken
Study design V: Case-Control Studies
Presentation transcript:

Andrews 3/27/00 SP1 Pregnancy Follow-up Studies Lessons from Glaxo Wellcome Experience

Andrews 3/27/00 SP2 Outline  Historical case study  Lessons learned  Future possibilities  Key issues

Points to Consider in Deciding When to Establish a Pregnancy Follow-up Study  Likelihood of 1st trimester exposure  Potentially large exposed population of sexually active women Ages  Animal data and relationship to effect on human fetus  Underlying medical condition  Medication’s mechanism of action  FDA pregnancy category rating

Andrews 3/27/00 SP4 Case-study: Acyclovir Background  Antiviral medicine to treat herpes simplex virus infections  Pregnancy registry established in 1984 due to: Potential for unintentional 1st trimester exposure to new chemical entityPotential for unintentional 1st trimester exposure to new chemical entity Historic precedent of less specific antiviral agents for toxic effectsHistoric precedent of less specific antiviral agents for toxic effects

Andrews 3/27/00 SP5 Acyclovir Study - Origins  Acyclovir Study established 1984 –Part of broad epidemiologic safety program –Joint effort with CDC –Objective: Monitor for risks of birth defects following antenatal acyclovir exposure –Duration: Use registry approach until other, more efficient, methods could address the question

Andrews 3/27/00 SP6 Design Considerations (1) Exposures of potential interest –Oral acyclovir –IV acyclovir –Topical acyclovir –Maternal exposures –Paternal exposures –Trimester 1, 2, 3 Outcomes of potential interest –Overall major birth defects –Specific birth defects –Minor events –Delayed development –Maternal complications –Spontaneous abortion

Andrews 3/27/00 SP7 Design Considerations (2)  Objective: Estimate risk of major birth defects  Cohort study neither ethical nor feasible because outcomes are too rare  Case-control not feasible –Exposures too rare –No a priori hypotheses  No existing data resources available and sufficient

Andrews 3/27/00 SP8 Design Considerations (3)  Exposure registration and followup study –Prospective enrollment required –Birth defect comparator needed (population rate) –Outcomes: birth defects consistent with CDC definitions –Other outcomes not within scope (e.g., maternal events, spontaneous abortion) because different / more data neededdifferent / more data needed methods not appropriatemethods not appropriate

Inclusion Criteria Trimester 1 Trimester 2 Trimester 3Birth Ultrasound 16 weeks PROSPECTI VE (included) Case reported before outcome known RETROSPECTIVE (excluded) Case reported after outcome known

Andrews 3/27/00 SP10 Method - Data Collection  Initial data collected at enrollment –Exposure, timing, EDD, prenatal testing –Potential confounders specific to the study  Basic information from single reporter –Likely to be motivated –Likely to have exposure and outcome information –Will not require additional steps

Methods - Follow-Up  Follow-Up: –Form sent to health professional at EDD –Monthly reminders until data obtained –Patient identifiers (not names) used and deleted at completion –Thank you letter with encouragement to register other exposures, and to solicit longer term outcomes, if known

Andrews 3/27/00 SP12 Targeted Follow-Up of Birth Defects  Initiated by registry staff  Targeted to specific birth defect cases reported  Based on CDC teratology review  Could include questions from GW Drug Surveillance M.D.

Methods - Analysis  Separate prospective/retrospective reports  Estimate birth defect risk (proportion) from prospective reports  Compare risk against “expected” risk  Evaluate specific birth defects  Analyze defects for evidence of patterns or uniqueness  Review of all data by Advisory Committee

Andrews 3/27/00 SP14 Recruitment  Challenge: Encourage enrollment without communicating an inappropriate message –Avoid implying drug should be used in pregnancy –Avoid suggesting a known risk exists  Options: –Use existing health information lines –Referrals from TIS, CDC, FDA –Medical newsletters, journals, MMWR –Scientific meetings, presentations –Package insert

Andrews 3/27/00 SP15 Sources of Calls and Referrals Registry CDC Health Care Providers Patients Clinical Trials Operating Companies International Sources Genetic Counselors Company Sales Force Teratogen Information Services Other Manufacturers

Advisory Committee  Reviewed data  Assisted in disseminating information  Members represented - Centers for Disease Control and Prevention - Academic medical practitioners/epidemiologists - Glaxo Wellcome medical department - Could be expanded to include other disciplines, groups  Expertise in STDs, Obstetrics, Teratology, Pediatrics, Epidemiology

Andrews 3/27/00 SP17 Acyclovir Registry -- Prospective Reports June April 1999

Andrews 3/27/00 SP18 Results: Birth Defects  First -Trimester Exposure: 19/ % (95% CI: 2.0%, 5.0%) 3.2% (95% CI: 2.0%, 5.0%)  Any Trimester Exposure: 28/ % (95% CI: 1.8%, 3.8%) 2.6% (95% CI: 1.8%, 3.8%)  Does not differ from general population

Andrews 3/27/00 SP19 Conclusions  No pattern among prospectively or retrospectively reported birth defects  Potential limitations should be recognized (underreporting, differential reporting, losses to follow-up)  Despite these limitations, these results are useful in the course of counseling women following inadvertent prenatal exposure

Andrews 3/27/00 SP20  Information useful to patients and physicians  Useful to GW in evaluation of safety  Information included in product label  Changed label from Category C to B  Study data informed the CDC STD Treatment Guidelines Value of the Study

Pregnancy Follow-up Studies  Acyclovir -- June 1984 (now closed)  Antiretrovirals a -- 1 Jan 1989  Lamotrigine -- 1 Sept 1992  Valacyclovir -- Jan 1995 (now closed)  Sumatriptan -- 1 Jan 1996  NA AED Pregnancy Registry a -- Nov 1996  Bupropion -- 1 Sept 1997  Naratriptan -- 1 Oct 1997 a Multi-company sponsored studies

Andrews 3/27/00 SP22 Lessons  Design must be targeted to the questions  Simplicity is essential in data gathering  Voluntary recruitment of sufficient numbers of relevant exposures is difficult  Follow-up is a challenge  Ideal must be balanced by practicality

Andrews 3/27/00 SP23 Ideal study design Probability of obtaining usefuldataProbability usefuldata MEDICATION SAFETY STUDIES

Andrews 3/27/00 SP24 Broad surveillance for increased risks of major birth defects ? Basic Approach Monitoring for specific birth defect? Case-control study Monitoring for subtle or delayed event? Targeted follow up study Yes NO Basic Approach Yes TAILOR DESIGN TO THE QUESTION

Andrews 3/27/00 SP25 SELECT THE METHOD APPROPRIATE TO THE OUTCOMES OF INTEREST  Basic registry designed to evaluate risk of major birth defects  Other outcomes can be better studied with different methods –spontaneous abortion –maternal outcomes –infant outcomes requiring long-term follow-up –infant outcomes requiring medical examination for confirmation

Andrews 3/27/00 SP26 Selecting the Right Approach High Low Sample Size Complexity Nature of Information Frequency of major birth defects Delayed effects Cross-drug comparison Frequency of all birth defects in first year

Andrews 3/27/00 SP27 Impact of Methods on Case Capture and Follow-up Consent required Number of Referral steps Complexity of data collection Duration of follow-up 100% ? 50 %

Andrews 3/27/00 SP28 Other Approaches Large linked databases offer promise  Identification of all exposures within a population  Not dependent on voluntary reporting  Follow-up information collected for other purposes  Sample size may be achievable if multiple populations can be used Case-Control studies remain useful

Andrews 3/27/00 SP29 Issues  New consent/IRB considerations must balance individuals’ interests with impediments to conducting voluntary registries. Regulations should facilitate, not hinder, public health monitoring functions  Adverse event reporting should follow study guidelines, not spontaneous guidelines  Value and use of information need to be better understood (confirm safety & identify new signals)